Allogeneic hematopoietic cell transplantation from alternative donors in acute myeloid leukemia.

Autor: Sugita J; Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan., Morita K; Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan., Konuma T; Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Yanada M; Department of Hematology and Oncology, Nagoya City University East Medical Center, 1-2-23 Wakamizu, Chikusa-ku, Nagoya, 464-8547, Japan. myanada@med.nagoya-cu.ac.jp.
Jazyk: angličtina
Zdroj: Annals of hematology [Ann Hematol] 2024 Aug 17. Date of Electronic Publication: 2024 Aug 17.
DOI: 10.1007/s00277-024-05944-0
Abstrakt: Allogeneic hematopoietic cell transplantation (HCT) potentially provides a cure for patients with acute myeloid leukemia (AML) who are unlikely to be cured with chemotherapy alone. Previously, human leukocyte antigen (HLA)-matched related donors were used exclusively, which made the procedure available for a limited proportion of patients. The introduction of high-resolution HLA-typing technology, innovations in immunosuppressive therapy, and improved supportive care measures have significantly changed the situation. Now, patients without a matched related donor have an ample opportunity to receive allogeneic HCT with the use of matched or mismatched unrelated donors, umbilical cord blood grafts, or haploidentical related donors. The outcomes of alternative donor transplantations have improved over the past decades, and the growth of unrelated donor registries as well as the donor diversification have enhanced the chance of finding a suitable donor. With multiple alternative donor choices available for most patients, the donor selection is becoming increasingly important. To discuss the optimal donor choice in case of unavailability of an HLA-matched related donor, this article reviews the existing literature of retrospective and prospective comparisons of different alternative donor transplantations in AML and discusses the current state-of-art modalities in allogeneic HCT using alternative donors.
(© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: